Skip to main content


Projects I. Rooman


Projects B. Neyns

Targeted Therapies (BRAF/MEK-inhibitors) (Dr. G. Awada)

  • TraMel-WT (PI Prof. Dr. B. Neyns): trial of Trametinib in patients with advanced pretreated BRAFV600 wild-type Melanoma
  • Combi-R2 (PI Prof. Dr. B. Neyns): Dabrafenib/Trametinib/Hydroxychloroquine for advanced pretreated BRAF V600 mutant melanoma

Myeloid Dendritic Cell Therapy (MYDC) (Dr. JK. Schwarze)

  • myDCTV (PI Prof. Dr. B. Neyns): intratumoral injection of autologous CD1c/CD141 (BDCA-1/BDCA-3)+ myDC plus Talimogene Laherparepvec (T-VEC)
  • myDAvlpNi (PI Prof. Dr. B. Neyns): intratumoral injection of autologous CD1c/CD141 (BDCA-1/BDCA-3)+ myDC, Avelumab, and Ipilimumab plus systemic Nivolumab

Checkpoint Inhibitors (Prof. Dr. B. Neyns)

  • GlitipNi: intra-tumoral Ipilimumab plus intravenous Nivolumab following the resection of recurrent Glioblastoma
  • LuSCID: Lung cancer treated with SBRT, Checkpoint Inhibitors and¬†myeloid Dendritic cells

PARP Inhibition in HRD Solid Tumors (Dr. S. Joris)

  • Precision 2 Study: Olaparib: efficacy of olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes
  • Whole exome sequencing on index patients in families with breast and pancreatic cancer

EGFR-Targeted Therapy (Prof. Dr. L. Decoster)

  • Afatinib: a prospective explorative open label Phase II study of Afatinib in the treatment of advanced cancers carrying a EGFR, HER2 or HER3 mutation
  • G-OncoCOACH (geriatric assessment): randomized study to investigate the effect of GA-directed interventions coordinated by the geriatric team and patient coaching versus interventions coordinated by oncologists in older adults with cancer treated with systemic therapy